港股異動丨藥明系逆勢上升,美民主黨議員反對《生物安全法案》
港股市場藥明系逆勢上升,其中,藥明生物盤中一度升2.71%報11.36港元,藥明康德一度升超4%報36.1港元,藥明合聯一度升超3%至20.42港元。另外,A股市場的華大基因盤中一度逆勢升3.62%報36.06元。消息面上,美國眾議院定於週一對《生物安全法案》進行表決。這個法案必須在眾議院和參議院獲得通過後,拜登總統才能簽署成為法律。美國民主黨籍資深眾議員Jim McGovern上週五表示,他將投票反對以國家安全為由限制與中國藥明生物、華大基因等其他生物技術公司開展業務的法案。他正試圖説服同僚和他一起投票反對。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.